Last updated: 11/07/2018 00:44:23
A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC).
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC).
Trial description: A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Ardizzoni A, Hansen H, Dombernowsky P, Topotecan, A new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office and the lung cancer cooperative group. J Clin Onc 15, 2090 1997.
Topotecan (t), a new active agent in the second-line treatment of refractory" and "sensitive" small-cell lung cancer (sclc). A. Ardizzoni, H. Hansen J. Wanders P. Dombernowsky T. Gamucci S. Kaplan P. Postmus 1. Hudson G. Giaccone J. Verweij EORTC Early Clinical Study Lung Cancer Cooperative Group 21st Congress of the European Society for Medical Oncology 11/1/1996 Vienna; Austria"
Wanders J et al, Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC), 1995; abstract at American Association for Cancer Research. Ardizzoni A et al. 1995; abstract at ECCO
Medical condition
Lung Cancer, Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
February 1993 to August 1995
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1995-14-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website